Erratum to Knockdown of HMGN5 suppresses the viability and invasion of human urothelial bladder cancer 5637 cells in vitro and in vivo[Med Oncol, (2015), 32:136, 10.1007/s12032-015-0594-y];Knockdown of HMGN5 suppresses the viability and invasion of human urothelial bladder cancer 5637 cells in vitro and in vivo

Medical Oncology

Volumn 32, Issue 4, 2015, Pages 1-

  Gan, Yu ^a   Tan, Jing ^a   Yang, Jianfu ^a   Zhou, Yihong ^a   Dai, Yingbo ^a   He, Leye ^a   Yao, Kun ^a   Tang, Yuxin ^a  

^a THE THIRD XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Cell viability; HMGN5; Invasion; RNA interference; Urothelial bladder cancer

Indexed keywords

CYCLIN D1; HIGH MOBILITY GROUP N PROTEIN; HIGH MOBILITY GROUP N PROTEIN 5; UNCLASSIFIED DRUG; UVOMORULIN; VASCULOTROPIN C; HMGN5 PROTEIN, HUMAN; MESSENGER RNA; SMALL INTERFERING RNA; TRANSACTIVATOR PROTEIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL ADHESION; CELL CYCLE; CELL INVASION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FLUORESCENCE MICROSCOPY; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHANGIOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; TUMOR GROWTH; UPREGULATION; UROTHELIAL BLADDER CANCER; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BLADDER TUMOR; CELL MOTION; CELL PROLIFERATION; DRUG SCREENING; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; HMGN PROTEINS; HUMANS; IN VITRO TECHNIQUES; MICE; MICE, INBRED BALB C; MICE, NUDE; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANS-ACTIVATORS; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84938059081     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-015-0611-1     Document Type: Erratum

References (35)

1. Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63(2):234–41. doi:10.1016/j.eururo.2012.07.033.
2. Jacobs BL, Lee CT, Montie JE. Bladder cancer in 2010: how far have we come? CA Cancer J Clin. 2010;60(4):244–72. doi:10.3322/caac.20077.
3. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet. 2009;374(9685):239–49. doi:10.1016/S0140-6736(09)60491-8.
4. Zhu N, Hansen U. Transcriptional regulation by HMGN proteins. Biochim Biophys Acta. 2010;1799(1–2):74–9. doi:10.1016/j.bbagrm.2009.11.006.
5. West KL. HMGN proteins play roles in DNA repair and gene expression in mammalian cells. Biochem Soc Trans. 2004;32(Pt 6):918–9. doi:10.1042/BST0320918.
6. Gerlitz G. HMGNs, DNA repair and cancer. Biochim Biophys Acta. 2010;1799(1–2):80–5. doi:10.1016/j.bbagrm.2009.10.007.
7. Motoyama N, Naka K. DNA damage tumor suppressor genes and genomic instability. Curr Opin Genet Dev. 2004;14(1):11–6. doi:10.1016/j.gde.2003.12.003.
8. Rochman M, Malicet C, Bustin M. HMGN5/NSBP1: a new member of the HMGN protein family that affects chromatin structure and function. Biochim Biophys Acta. 2010;1799(1–2):86–92. doi:10.1016/j.bbagrm.2009.09.012.
9. Jiang N, Zhou LQ, Zhang XY. Downregulation of the nucleosome-binding protein 1 (NSBP1) gene can inhibit the in vitro and in vivo proliferation of prostate cancer cells. Asian J Androl. 2010;12(5):709–17. doi:10.1038/aja.2010.39.
10. Qu J, Yan R, Chen J, Xu T, Zhou J, Wang M, et al. HMGN5: a potential oncogene in gliomas. J Neurooncol. 2011;104(3):729–36. doi:10.1007/s11060-011-0558-9.
11. Ji SQ, Yao L, Zhang XY, Li XS, Zhou LQ. Knockdown of the nucleosome binding protein 1 inhibits the growth and invasion of clear cell renal cell carcinoma cells in vitro and in vivo. J Exp Clin Cancer Res: CR. 2012;31:22. doi:10.1186/1756-9966-31-22.
12. Green J, Ikram M, Vyas J, Patel N, Proby CM, Ghali L, et al. Overexpression of the Axl tyrosine kinase receptor in cutaneous SCC-derived cell lines and tumours. Br J Cancer. 2006;94(10):1446–51. doi:10.1038/sj.bjc.6603135.
13. Wahafu W, He ZS, Zhang XY, Zhang CJ, Yao K, Hao H, et al. The nucleosome binding protein NSBP1 is highly expressed in human bladder cancer and promotes the proliferation and invasion of bladder cancer cells. Tumour Biol: J Int Soc Oncodevelopmental Biol Med. 2011;32(5):931–9. doi:10.1007/s13277-011-0195-0.
14. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25(4):402–8. doi:10.1006/meth.2001.1262.
15. Mao Q, Li Y, Zheng X, Yang K, Shen H, Qin J, et al. Up-regulation of E-cadherin by small activating RNA inhibits cell invasion and migration in 5637 human bladder cancer cells. Biochem Biophys Res Commun. 2008;375(4):566–70. doi:10.1016/j.bbrc.2008.08.059.
16. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 1995;9(10):1149–63.
17. Jeanes A, Gottardi CJ, Yap AS. Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene. 2008;27(55):6920–9. doi:10.1038/onc.2008.343.
18. Benest AV, Harper SJ, Herttuala SY, Alitalo K, Bates DO. VEGF-C induced angiogenesis preferentially occurs at a distance from lymphangiogenesis. Cardiovasc Res. 2008;78(2):315–23. doi:10.1093/cvr/cvm094.
19. Su JL, Yen CJ, Chen PS, Chuang SE, Hong CC, Kuo IH, et al. The role of the VEGF-C/VEGFR-3 axis in cancer progression. Br J Cancer. 2007;96(4):541–5. doi:10.1038/sj.bjc.6603487.
20. Rochman M, Postnikov Y, Correll S, Malicet C, Wincovitch S, Karpova TS, et al. The interaction of NSBP1/HMGN5 with nucleosomes in euchromatin counteracts linker histone-mediated chromatin compaction and modulates transcription. Mol Cell. 2009;35(5):642–56. doi:10.1016/j.molcel.2009.07.002.
21. Zhou X, Yuan B, Yuan W, Wang C, Gao R, Wang J. The expression and clinical significance of high mobility group nucleosome binding domain 5 in human osteosarcoma. Tumour Biol: J Int Soc Oncodevelopmental Biol Med. 2014;35(7):6539–47. doi:10.1007/s13277-014-1825-0.
22. Weng M, Song F, Chen J, Wu J, Qin J, Jin T, et al. The high-mobility group nucleosome-binding domain 5 is highly expressed in breast cancer and promotes the proliferation and invasion of breast cancer cells. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2014. doi:10.1007/s13277-014-2715-1.
23. Pogna EA, Clayton AL, Mahadevan LC. Signalling to chromatin through post-translational modifications of HMGN. Biochim Biophys Acta. 2010;1799(1–2):93–100. doi:10.1016/j.bbagrm.2009.11.018.
24. Lambeth LS, Smith CA. Short hairpin RNA-mediated gene silencing. Methods Mol Biol. 2013;942:205–32. doi:10.1007/978-1-62703-119-6_12.
25. Rochman M, Taher L, Kurahashi T, Cherukuri S, Uversky VN, Landsman D, et al. Effects of HMGN variants on the cellular transcription profile. Nucleic Acids Res. 2011;39(10):4076–87. doi:10.1093/nar/gkq1343.
26. van Rhijn BW, Burger M, Lotan Y, Solsona E, Stief CG, Sylvester RJ, et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol. 2009;56(3):430–42. doi:10.1016/j.eururo.2009.06.028.
27. Zavadil J, Haley J, Kalluri R, Muthuswamy SK, Thompson E. Epithelial-mesenchymal transition. Cancer Res. 2008;68(23):9574–7. doi:10.1158/0008-5472.CAN-08-2316.
28. De Wever O, Pauwels P, De Craene B, Sabbah M, Emami S, Redeuilh G, et al. Molecular and pathological signatures of epithelial-mesenchymal transitions at the cancer invasion front. Histochem Cell Biol. 2008;130(3):481–94. doi:10.1007/s00418-008-0464-1.
29. Yun SJ, Kim WJ. Role of the epithelial-mesenchymal transition in bladder cancer: from prognosis to therapeutic target. Korean J Urol. 2013;54(10):645–50. doi:10.4111/kju.2013.54.10.645.
30. Bryan RT, Tselepis C. Cadherin switching and bladder cancer. J Urol. 2010;184(2):423–31. doi:10.1016/j.juro.2010.04.016.
31. Zhang HH, Qi F, Shi YR, Miao JG, Zhou M, He W, et al. RNA interference-mediated vascular endothelial growth factor-C reduction suppresses malignant progression and enhances mitomycin C sensitivity of bladder cancer T24 cells. Cancer Biother radiopharm. 2012;27(5):291–8. doi:10.1089/cbr.2010.0919.
32. Mylona E, Magkou C, Gorantonakis G, Giannopoulou I, Nomikos A, Zarogiannos A, et al. Evaluation of the vascular endothelial growth factor (VEGF)-C role in urothelial carcinomas of the bladder. Anticancer Res. 2006;26(5A):3567–71.
33. Huang KJ, Sui LH. The relevance and role of vascular endothelial growth factor C, matrix metalloproteinase-2 and E-cadherin in epithelial ovarian cancer. Med Oncol. 2012;29(1):318–23. doi:10.1007/s12032-010-9817-4.
34. Gotte M, Kersting C, Radke I, Kiesel L, Wulfing P. An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ. Breast cancer Res: BCR. 2007;9(1):R8. doi:10.1186/bcr1641.
35. Yamashita T, Uramoto H, Onitsuka T, Ono K, Baba T, So T, et al. Association between lymphangiogenesis-/micrometastasis- and adhesion-related molecules in resected stage I NSCLC. Lung Cancer. 2010;70(3):320–8. doi:10.1016/j.lungcan.2010.02.013.